Quarterly report pursuant to Section 13 or 15(d)

4. Commitments and Contingencies (Details Narrative)

v3.20.2
4. Commitments and Contingencies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Research and development expense $ 1,042,274 $ 325,634 $ 3,147,636 $ 416,671  
Technology Rights And Development Agreement [Member] | Houston Pharmaceuticals [Member]          
Contractual obligation 0 $ 45,833 0 45,833 $ 45,833
Royalty income     150,000 $ 0  
Patent and Technology License Agreement [Member] | UTMDACC [Member]          
Contractual obligation 200,000   200,000    
License fee     138,018    
Sponsored Research Agreement [Member] | UTMDACC [Member]          
Contractual obligation $ 734,000   734,000    
Research and development expense     $ 334,000